TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06659445: Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Sponsor: ONL Therapeutics · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 324 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,556,400

Rescue Site Savings

+$1,693,200

Unlock Full NCT06659445 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06659445 Rescue Dossier →